The Union government has told the Supreme Court that concerns over high medicine prices require attention, as the court examines the affordability of drugs outside the existing scheduled-price-control framework.
The hearing brings a long-running public-policy tension into focus: India must encourage pharmaceutical availability and innovation while ensuring that essential treatment does not become unaffordable for patients. Medicine costs can account for a substantial share of out-of-pocket healthcare spending, making the structure of price regulation directly relevant to household finances.
What the court questioned
According to reporting on the hearing, the bench questioned the rationale for controlling prices of selected scheduled medicines while other medicines can be sold outside those specific ceilings. The government acknowledged that high prices can create a problem for patients and indicated that it would examine possible responses.
The comments do not themselves change drug prices or expand the list of medicines under price control. Any policy revision would require action by the government and relevant regulatory authorities under the applicable legal framework.
How price control works
India’s pharmaceutical pricing system uses the National List of Essential Medicines and the Drug Price Control Order as important components of regulation. The National Pharmaceutical Pricing Authority fixes or monitors prices for medicines covered by the framework and can take action under the rules.
However, the pharmaceutical market includes thousands of formulations, brands and therapeutic alternatives. Policymakers therefore face questions about which medicines should be directly controlled, how ceilings should be calculated and how to avoid shortages or unintended market distortions.
Why the case matters politically
Healthcare affordability is both a regulatory and governance issue. Governments are judged not only on public hospitals and insurance schemes but also on whether medicines remain accessible to people who buy treatment directly from pharmacies or private hospitals.
The court’s scrutiny may prompt the Centre to explain whether the current distinction between scheduled and non-scheduled medicines adequately protects patients. Industry stakeholders, meanwhile, are likely to focus on predictability, production costs and the effect of broader controls on supply.
For patients, the key outcome will be whether the proceedings lead to a clearer and more effective mechanism for preventing unreasonable pricing while maintaining reliable access to medicines. The government has not yet announced a final policy change.
